Revolution Medicines (RVMD) Insider Borellini Buys 1,191 Shares

Flavia Borellini acquired 1,191 shares of Revolution Medicines, Inc. ($RVMD) on June 18, 2026. This transaction was part of a broader day of insider buying at the Nasdaq-listed biotechnology firm, which is currently working on advanced treatments for difficult-to-treat cancers. The move came during a period of high activity for the company's leadership and followed several major analyst updates.

Recent Insider Activity at Revolution Medicines

The purchase by Flavia Borellini was just one of several acquisitions on June 18, 2026. On that same day, Sushil Patel and Lorence Kim each acquired 3,127 shares of the company. These buys occurred alongside more complex moves by other executives. For instance, Chief Financial Officer Jack Anders had a busy month; on June 24, 2026, he acquired 20,000 shares but also sold 20,000 shares at an average price of $168.33 through a pre-planned trading arrangement. Earlier, on June 16, 2026, Anders sold 2,722 shares at $156.12, while President and CEO Mark Goldsmith sold 10,020 shares at that same price point under a Rule 10b5-1 plan.

Revolution Medicines Stock Performance

On Wednesday, shares of Revolution Medicines were priced at $169.51. The stock has seen significant movement over the past year, trading between a 52-week low of $42.18 and a high of $224.31. While the current price has pulled back from its recent 50-day moving average of $199.22, it stays comfortably above its 200-day moving average of $140.41. This long-term upward trend reflects the market's ongoing interest in the company's clinical pipeline.

Analysts Set New Price Targets

Financial firms have been active in updating their expectations for the stock throughout late 2026. On October 16, 2026, William Blair started coverage with an Outperform rating. Just a day earlier, Needham reiterated its Buy rating with a $275.00 price target. RBC Capital has also been bullish, maintaining an Outperform rating and lifting its target to $260.00 on October 14, 2026. Other optimistic views come from Brookline Capital, which initiated a Buy rating with a $318.00 target on September 28, 2026, and Morgan Stanley, which set an Overweight rating and a $255.00 target on September 10, 2026. Across 20 analyst opinions, the stock holds a consensus recommendation of Strong Buy.

Precision Oncology Research

Revolution Medicines is a clinical-stage company based in Redwood City, California, that specializes in precision oncology. It focuses on developing therapies for RAS-addicted cancers, which are often resistant to traditional treatments. Its lead candidates, including daraxonrasib, are currently being evaluated in major phase 3 trials. The company's work is highly technical, targeting specific genetic variants to stop tumor growth in solid tumors and pancreatic cancers.

What to Watch at Revolution Medicines, Inc.

Investors are looking toward the company's next earnings update, which is scheduled for November 4, 2026. While the company is not yet profitable and reported a loss of $8.87 per share, it maintains a strong liquidity position with a current ratio of 11.37. This financial cushion is vital as it continues to fund expensive late-stage clinical trials. Future filings will reveal if insiders continue to hold their positions or if the recent wave of buying signals a longer-term shift in sentiment.